2cureX presents positive clinical data from its IndiTreat® CRC trial at ESMO in Barcelona
2cureX AB (“2cureX”) today announces that the company will present positive data from the IndiTreat® clinical validation trial within colorectal cancer (“CRC”) at the ESMO (European Society for Medical Oncology) World Congress on Gastrointestinal Cancer 2018 in Barcelona.The IndiTreat® colorectal cancer (CRC) clinical trial is separated into two phases: a performance evaluation part and an interventional randomization part. The first part of the clinical study is getting close to a positive conclusion. The interim results, including 14 patients, show a 71% success rate with regard to